No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Europe's drug regulator has backed Moderna's novel vaccine for respiratory syncytial virus, the US pharmaceutical firm announced on Friday.
Moderna said the European Medicines Agency's Committee for Medicinal Products for Human Use had adopted a "positive opinion" recommending the granting of marketing authorisation in the European Union for the vaccine, known as mRESVIA.
The opinion was based on positive data from phase 3 clinical trials, which featured 37,000 adults in 22 countries, Moderna added.
Moderna's mRESVIA vaccine is intended to protect adults aged 60 and over from lower respiratory track disease caused by RSV infection. RSV is a highly contagious seasonal respiratory virus, and causes around 160,000 adult hospital admissions every year in the EU.
It was developed using Moderna's mRNA platform, which was used in its blockbuster Covid vaccine.
Stephane Bancel, chief executive, said: "The positive opinion...highlights the innovation and adaptability of our mRNA platform.
"mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration.
"We look forward to the decision on an EU-wide marketing authorisation from the European Commission."
As at 1330 BST, shares in Nasdaq-listed Moderna were up 2% in pre-market trading.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.